1 / 38

Hypertension What to do when you don’t know what to do! Fiona Stewart Auckland Heart Group

Hypertension What to do when you don’t know what to do! Fiona Stewart Auckland Heart Group Auckland City Hospital 2 nd Sept 2011. Hypertension NZ Heart Foundation Recommendations. Essential Hypertension BP < 140/85 Hypertension with Diabetes BP < 130/80

vivi
Download Presentation

Hypertension What to do when you don’t know what to do! Fiona Stewart Auckland Heart Group

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hypertension What to do when you don’t know what to do! Fiona Stewart Auckland Heart Group Auckland City Hospital 2nd Sept 2011

  2. HypertensionNZ Heart Foundation Recommendations Essential Hypertension BP < 140/85 Hypertension with Diabetes BP < 130/80 Renal disease BP < 130/80 Proteinuria > 1g/dBP < 125/75 Age > 80 BP < 150/

  3. Blood Pressure Measurement • Correct cuff size • Sitting x2 at 2 minute intervals • Standing BUT in patients with borderline BPs • Single recordings are unreliable • Multiple clinic recordings correlate poorly with ABU • Home BP monitoring is not much better Consider Repeat visit Nurse check (“white coat hypertension”) Home BP monitoring Ambulatory 24hr BP monitoring

  4. Home BP Measurements

  5. Ambulatory Blood Pressure Monitoring

  6. Blood Pressure Review • History • Other illnesses (cardiovascular disease, diabetes, renal disease, gout) • Family history • Lifestyle assessment • Smoking, alcohol (max 1-2/d) salt intake, liquorice ingestion, weight, exercise, stress • Basic tests • FBC, U + E, urate, creat, eGFR, gluc, lipids, MSU • ECG

  7. Blood Pressure ReviewAdditional Tests Indication • Abnormal screening tests • Young • BP severe or hard to control • Renin, aldosterone, cortisol • 24h U metanephrines • Renal scan and doppler study • Echocardiogram – LVH, ascending aorta

  8. Prehypertension • Linear increase in risk from BP 115/75 • ↑20mmHg SBP or ↑10mmHg DBP doubles mortality from cardiovascular disease • BP 120-139/80-89 “prehypertension”

  9. Prehypertension Management • Weight • Salt intake (including soya sauce) • Liquorice ingestion • Alcohol • Stress • Exercise • Contributing drugs (NSAIDs)

  10. Hypertension - Treatment • Systolic BP better predictor of adverse cardiovascular events especially in elderly • Persistent BP > 140/85 → treat • Over 80 years – aim for SBP<150 • Always check standing BP

  11. Which Antihypertensive is Best?ALLHAT Trial • Chlorthalidone 12.5 – 25mg • Amlodipine • Lisinopril • Doxazosin

  12. Doxazosin or Chlorthalidone?ALLHAT Trial

  13. ALLHAT TrialDoxazosin and Chlorthalidone

  14. ALLHAT TrialBP Control

  15. ALLHAT Trial • Target BP < 140/90 • 67% achieved target • 2/3 were taking 2+ agents • 1/4 were taking 3+ agents • Expect to need multiple medications to control BP

  16. ALLHAT TrialFatal Cardiac Event and Nonfatal MI

  17. ACCOMPLISH Trial • ACEI + Amlodipine • ACEI + Hydrochlorothiazide

  18. ACCOMPLISH Trial

  19. ACCOMPLISH Trial Cardiovascular Events

  20. ACCOMPLISH Trial • 21% Reduction in CV death, MI, CVA over 3 years • NNT to prevent one major event = 77 • 37% were taking > 3 agents

  21. HypertensionTreatment Choice Assess comorbidity. Multiple drugs are usually necessary First Line • Thiazides • ACEI/ARB • CCB Second Line • Beta blockers Third Line • Spironolactone • Alpha blockers • Clonidine Fourth Line • Ardian radiofrequency ablation of renal artery Statin

  22. Treatment of Hypertension in the Very Elderly > 80HYVET trial • Patients aged > 80 • SBP >160mmHg, DBP < 110mmHg • Indapamide 1.5mg + Perindopril 2-4mg vs placebo • Target BP 150/80

  23. Blood pressure separation 15 mmHg Median follow-up 1.8 years 6 mmHg

  24. All stroke (30% reduction) Placebo P=0.055 Indapamide SR ±perindopril Placebo IndapamideSR ±perindopril

  25. Total Mortality (21% reduction) Placebo P=0.019 Indapamide SR ±perindopril Placebo IndapamideSR ±perindopril

  26. Fatal Stroke (39% reduction) Placebo Indapamide SR ±perindopril P=0.046 Placebo IndapamideSR ±perindopril

  27. Heart Failure (64% reduction) Placebo P<0.0001 IndapamideSR ±perindopril Placebo IndapamideSR ±perindopril

  28. 0.1 0.2 0.5 0 2 ITT – Summary

  29. Starting Antihypertensive Treatment • Change only one medication at a time • Arrange follow up BP measurements (L+S) • Check electrolytes with diuretics • Escalate early to a second agent • Feedback results to the patient

  30. BP Remains Elevated • Confirm hypertension with 24hr monitor • Check for secondary causes • Renal scan ? Renal artery stenosis • Cortisol, renin, aldosterone, metanephrines • Lifestyle adjustments – stress, salt • Compliance • Optimal medication dose and frequency

  31. Optimising Medication • Thiazides • Chlorthalidone more effective than HCZ • ACEI • Cilazapril and lisinopril – daily dose • Enalapril and quinapril – bd dose • Angiotensin II Blockers • Titrate dose to 32mg candesartan, 100mg losartan • CCBs • Amlodipine and felodipine 10mg

  32. Chronic Hypertension and Pregnancy Measurement • Sitting • DBP 4thKorotkoff sound DBP <90mmHg from conception to 20/40 is strongly correlated with lower rates of pre-eclampsia ACEI and ARB are contraindicated from 6 weeks gestation. ACEI are safe with breast feeding. Metoprolol, oxprenolol and labetalol are associated with a better fetal outcome than other beta-blockers Methydopa has a long record of safety in pregnancy CCBs are well tolerated in pregnancy

  33. The kidney as origin of sympathetic drive carried centrally via renal afferent sympathetic nerves generating central sympathetic drive Vasoconstriction Atherosclerosis Hypertrophy Arrhythmia Oxygen Consumption Sleep Disturbances Renal Afferent Nerves Insulin Resistance Renal Efferent Nerves ↑ Renin Release  RAAS activation ↑ Sodium Retention ↓ Renal Blood Flow

  34. Radiofrequency energy can ablate the renal sympathetic nerves

  35. Symplicity HTN-1 Lancet. 2009;373:1275 • First-in-man, non-randomized • 45 patients with resistant HTN (SBP ≥160 mmHg on ≥3 anti-HTN drugs, including a diuretic) • Expanded cohort of patients (n=153) • 24-month follow-up 35

  36. Significant, Sustained BP Reduction BP change (mmHg) 36

  37. Primary Endpoint: 6-Month Office BP ∆ from Baseline to 6 Months (mmHg) Systolic Diastolic Diastolic Systolic 33/11 mmHg difference between RDN and Control (p<0.0001) • 84% of RDN patients had ≥ 10 mmHg reduction in SBP • 10% of RDN patients had no reduction in SBP Symplicity HTN-2 Investigators. Lancet. 2010;376:1903. 37

  38. Changes in Glucose Toleranceat 3 Months after Renal Denervation Mahfoud et al. European Society of Cardiology. 2010.

More Related